Financial Performance - The company's operating revenue for the reporting period was CNY 345,286,102.13, representing a year-on-year increase of 13.68%[5] - The total profit for the period was CNY 97,744,458.73, reflecting a year-on-year growth of 20.15%[5] - Net profit attributable to shareholders was CNY 85,815,891.13, up 21.01% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 80,393,732.37, an increase of 18.16% year-on-year[5] - Basic earnings per share reached CNY 1.34, marking a 20.72% increase from the previous year[5] Assets and Equity - Total assets at the end of the reporting period amounted to CNY 596,510,511.68, a year-on-year increase of 20.25%[6] - Shareholders' equity attributable to the company was CNY 497,675,062.33, reflecting a growth of 21.07% year-on-year[6] Growth Drivers - The increase in profit was driven by market expansion and significant growth in product lines such as life information monitoring and airway management series[6] - The company experienced notable growth in regions including international markets, East China, North China, and Northeast China[6] - The increase in total assets and equity was attributed to ongoing construction projects and the expansion of production, sales, and procurement scales[6]
海圣医疗(920166) - 2025 Q4 - 年度业绩